Compare RGNX & NXJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGNX | NXJ |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.6M | 503.5M |
| IPO Year | 2015 | N/A |
| Metric | RGNX | NXJ |
|---|---|---|
| Price | $6.97 | $12.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 90.1K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.27% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $5.46 | $11.06 |
| 52 Week High | $16.19 | $12.90 |
| Indicator | RGNX | NXJ |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 55.04 |
| Support Level | $5.46 | $11.94 |
| Resistance Level | $10.13 | $12.76 |
| Average True Range (ATR) | 0.66 | 0.09 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 25.57 | 69.38 |
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.